Companies Urged to Keep COVID-19 Drugs Affordable Amid Pandemic
May 8th, 2020
Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That’s when most drugs get price tags.
Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It’s unclear when that decision might be made. Read the full article at NPR.
In early April investor members of the Interfaith Center on Corporate Responsibility (ICCR) sent letters to the CEOs of fourteen pharmaceutical companies calling for a collaborative approach in the development of health technologies, including diagnostics, treatments and a vaccine in the global fight against Covid-19.
The letter was sent to AbbVie (ABBV); Amgen (AMGN); Biogen (BIIB); Bristol-Myers Squibb (BMY); Gilead (GILD); GlaxoSmithKline (GSK); Eli Lilly (LLY); Johnson & Johnson (JNJ); Merck (MRK); Pfizer (PFE); Novartis (NVS); Roche (RHHBY); Sanofi (SNY) and; Vertex (VRTX). Read more.
As companies go virtual with Annual General Meetings, shareholders are finding ways to still participate in the process and convey concerns. ICCR has launched #AskTheCEO, a campaign to capture shareholders’ questions at these virtual meetings.
Visit ICCR’s website to read more about their #AskTheCEO campaign and watch shareholder videos.